Let's hope so. I can only hope that the plan, if it goes well, is to use the data to further expedite the trials as well. If we can continue to prove safety and also great efficacy with better vision patients, it wouldn't make sense to take a step "down" to worse vision patients.

The fact that they allowed the patients to be treated at once rather than one at a time is also re-assuring. It shows that the FDA must have a lot of confidence when it comes to safety. The folks with better vision have more to lose.

I suspect we have a lot to look forward to as these patients are treated.

Yahoo! Finance Worldwide

Quotes are real-time for NASDAQ, NYSE, and NYSEAmex when available. See also delay times for other exchanges. Quotes and other information supplied by independent providers identified on the Yahoo! Finance partner page. Quotes are updated automatically, but will be turned off after 25 minutes of inactivity. Quotes are delayed at least 15 minutes. All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.